Varda Space Industries is an In-Space Infrastructure & Servicing company founded in 2020 and based in El Segundo, United States. It has raised $579M in total funding, most recently a Series D in 2026 at a $1.6B valuation.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Sep 30, 2026 | Series D | $251M | $1.6B | Lux Capital, Natural Capital |
| Jul 10, 2025 | Series C | $187M | — |
| Natural Capital, Shrug Capital |
Autonomous orbital manufacturing and return vehicles that process pharmaceuticals and materials in microgravity then reenter Earth's atmosphere and land on demand. Varda has flown a growing cadence of missions, with W-5 and W-6 both completing successful reentries in 2026 — W-6 landing at the Koonibba Test Range in South Australia and validating autonomous navigation and advanced thermal-protection systems. Each capsule carries Air Force Research Laboratory hypersonic-reentry payloads alongside commercial pharmaceutical experiments, making Varda a dual-use defense reentry testbed and commercial drug manufacturer simultaneously.
Integrated microgravity processing system that crystallizes small-molecule drugs and biologics—including monoclonal antibodies—in orbit, where the absence of gravity enables superior crystal uniformity and purity versus Earth-based production. Varda's first client, Improved Packing for Proteins (ritonavir experiments), demonstrated pharmaceutical-grade results. A $187M Series C in 2025 scaled operations toward a recurring cadence of reentries, cementing Varda as the first commercial in-space factory.